| Myelodysplastic Syndrome Post Cytotoxic Therapy studied in …STUDIED_INderived15 of 15show fewer |
|---|
| → studied in | NCT01885689Phase 2 · active not recruiting Clofarabine and Melphalan Before Donor Stem Cell Transplant in Treating Patients With Myelodysplasia, Acute Leukemia in Remission, or Chronic Myelomonocytic Leukemia · condition mapped ALIAS · 15 trials mapped (7 active) | — | — | Myelodysplastic Syndrome Post Cytotoxic Therapy | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04726241Phase 1/Phase 2 · recruiting The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study · condition mapped ONTOLOGY_EXACT · 15 trials mapped (7 active) | — | — | Myelodysplastic Syndrome Post Cytotoxic Therapy | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02727803Phase 2 · recruiting Personalized NK Cell Therapy in CBT · condition mapped ALIAS · 15 trials mapped (7 active) | — | — | Myelodysplastic Syndrome Post Cytotoxic Therapy | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07675967recruiting Clonal Hematopoiesis Chemotherapy and Radiation Effects Study · condition mapped ALIAS · 15 trials mapped (7 active) | — | — | Myelodysplastic Syndrome Post Cytotoxic Therapy | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04550442Phase 1/Phase 2 · terminated Venetoclax and Azacitidine for the Treatment of Relapsed or Refractory High-Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia · condition mapped ALIAS · 15 trials mapped (7 active) | — | — | Myelodysplastic Syndrome Post Cytotoxic Therapy | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05146739Phase 1 · active not recruiting Highest Dose of Uproleselan in Combination With Fludarabine and Cytarabine for Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Mixed Phenotype Acute Leukemia Relapsed or Refractory That Expresses E-selectin Ligand on the Cell Membrane · condition mapped ONTOLOGY_EXACT · 15 trials mapped (7 active) | — | — | Myelodysplastic Syndrome Post Cytotoxic Therapy | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05292664Phase 1 · recruiting Venetoclax Basket Trial for High Risk Hematologic Malignancies · condition mapped ALIAS · 15 trials mapped (7 active) | — | — | Myelodysplastic Syndrome Post Cytotoxic Therapy | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05316701Phase 3 · active not recruiting Precision-T: A Randomized Study of Orca-T in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies · condition mapped ALIAS · 15 trials mapped (7 active) | — | — | Myelodysplastic Syndrome Post Cytotoxic Therapy | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04160052Phase 1/Phase 2 · terminated Venetoclax and Azacitidine for the Treatment of High-Risk Recurrent or Refractory Myelodysplastic Syndrome · condition mapped ALIAS · 15 trials mapped (7 active) | — | — | Myelodysplastic Syndrome Post Cytotoxic Therapy | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02658487Phase 2 · completed Vosaroxin and Infusional Cytarabine in Treating Patients With Untreated Acute Myeloid Leukemia · condition mapped ALIAS · 15 trials mapped (7 active) | — | — | Myelodysplastic Syndrome Post Cytotoxic Therapy | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01823198Phase 1/Phase 2 · completed Donor Natural Killer Cells and Donor Stem Cell Transplant in Treating Patients With High Risk Myeloid Malignancies · condition mapped ALIAS · 15 trials mapped (7 active) | — | — | Myelodysplastic Syndrome Post Cytotoxic Therapy | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03096782Phase 2 · completed Umbilical Cord Blood Transplant With Added Sugar and Chemotherapy and Radiation Therapy in Treating Patients With Leukemia or Lymphoma · condition mapped ALIAS · 15 trials mapped (7 active) | — | — | Myelodysplastic Syndrome Post Cytotoxic Therapy | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03272633early Phase 1 · terminated Irradiated Donor Cells Following Stem Cell Transplant in Controlling Cancer in Patients With Hematologic Malignancies · condition mapped ALIAS · 15 trials mapped (7 active) | — | — | Myelodysplastic Syndrome Post Cytotoxic Therapy | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02960646Phase 1 · completed Engineered Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies · condition mapped ALIAS · 15 trials mapped (7 active) | — | — | Myelodysplastic Syndrome Post Cytotoxic Therapy | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01619761Phase 1 · unknown NK Cells in Cord Blood Transplantation · condition mapped ALIAS · 15 trials mapped (7 active) | — | — | Myelodysplastic Syndrome Post Cytotoxic Therapy | 1 | Observed | clinicaltrials | graph → |